Zymeworks BC Inc. Forms 3, 4 and 5: Restricted Stock Units and Performance Rights
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 27 rows, 27 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-11-10: Reporting owner Josephson Neil; Form 4; Security Restricted Stock Unit; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-03-10: Reporting owner Klompas Neil A; Form 4; Security Restricted Stock Unit; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-03-10: Reporting owner Klompas Neil A; Form 4; Security Restricted Stock Unit; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2022-03-10: Reporting owner Josephson Neil; Form 4; Security Restricted Stock Unit; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-11-10 | Josephson Neil Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,885 11,772 owned after | $0.00 | 2022-11-14 | |
| 2022-03-10 | Klompas Neil A Officer (Chief Operating Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 2,500 owned after | $0.00 | 2022-03-11 | |
| 2022-03-10 | Klompas Neil A Officer (Chief Operating Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,708 5,417 owned after | $0.00 | 2022-03-11 | |
| 2022-03-10 | Josephson Neil Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −729 730 owned after | $0.00 | 2022-03-11 | |
| 2022-03-10 | Josephson Neil Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,666 3,334 owned after | $0.00 | 2022-03-11 | |
| 2022-03-04 holding as of filing | Astle Christopher Officer (SVP & Chief Financial Officer) | 3 | Restricted Stock Unit Derivative · Direct | Holding | no price filed | 2022-03-04 | ||
| 2021-11-10 | Josephson Neil Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,657 17,657 owned after | $0.00 | 2021-11-12 | |
| 2021-05-25 holding as of filing | Josephson Neil Officer (Interim Chief Medical Officer) | 3 | Restricted Stock Unit Derivative · Direct | Holding | no price filed | 2021-05-25 | ||
| 2021-05-25 holding as of filing | Josephson Neil Officer (Interim Chief Medical Officer) | 3 | Restricted Stock Unit Derivative · Direct | Holding | no price filed | 2021-05-25 | ||
| 2021-04-13 | Priour James Officer (Chief Commercial Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,266 4,534 owned after | $0.00 | 2021-04-13 | |
| 2021-03-10 | O'Driscoll Kathryn Officer (Chief People Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,354 2,709 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | O'Driscoll Kathryn Officer (Chief People Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Priour James Officer (Chief Commercial Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,250 6,250 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Polverino Anthony J. Officer (Chief Scientific Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Polverino Anthony J. Officer (Chief Scientific Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,125 8,125 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Tehrani Ali Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,708 15,417 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Tehrani Ali Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | HAUSMAN DIANA Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | HAUSMAN DIANA Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,125 8,125 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Klompas Neil A Officer (Chief Financial Officer) | 4 | Restricted Stock Unit Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 5,000 owned after | $0.00 | 2021-03-12 | |
| 2021-03-10 | Klompas Neil A Officer (Chief Financial Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,125 8,125 owned after | $0.00 | 2021-03-12 | |
| 2021-02-03 holding as of filing | Priour James Officer (Chief Commercial Officer) | 3 | Restricted Stock Unit Derivative · Direct | Holding | no price filed | 2021-02-03 | ||
| 2020-03-10 | O'Driscoll Kathryn Officer (Chief People Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,063 4,063 owned after | $0.00 | 2020-03-11 | |
| 2020-03-10 | Polverino Anthony J. Officer (Chief Scientific Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $0.00 | 2020-03-11 | |
| 2020-03-10 | HAUSMAN DIANA Officer (Chief Medical Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $0.00 | 2020-03-11 | |
| 2020-03-10 | Klompas Neil A Officer (Chief Financial Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $0.00 | 2020-03-11 | |
| 2020-03-10 | Tehrani Ali Director, Officer (Chief Executive Officer) | 4 | Restricted Stock Unit Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,125 23,125 owned after | $0.00 | 2020-03-11 |